New drug combo aims to stop Leukemia's return after transplant
NCT ID NCT07493408
Summary
This study is testing whether adding a new drug called asciminib to the standard post-transplant medication helps prevent two aggressive types of leukemia from coming back. It will involve about 45 adults who have already received a stem cell transplant. Researchers will compare the new combination to the standard treatment alone to see if it improves survival and is well-tolerated.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLASTIC TRANSFORMATION OF CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Hong Kong
Hong Kong, Hong Kong
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.